gynae/breast Flashcards
featurs of benign breast lumps on examination
Soft, mobile, fluctuant, ?painful
features of a malignant breast lump on examination
Hard, irregular, painless, immobile, Tethered skin, skin dimpling, nipple retraction
triple assessment breast lumps
Hx + Exam
Imaging: Mammogram 🡪 US
+/- biopsy
2ww for breast lumps
aged 30 and over and have an unexplained breast lump with or without pain or
aged 50 and over with any of the following symptoms in one nipple only: discharge, retraction or other changes of concern
breast screening
NHS Breast Screening Programme is offered to women between the ages of 50-70 years. Women are offered a mammogram every 3 years. After the age of 70 years women may still have mammograms but are ‘encouraged to make their own appointments’.
features fibroadenoma
Mobile, firm breast lumps. No increase in risk of malignancy. ‘breast mice’. Common <30
mx fibroadenoma
If >3cm surgical excision is usual, Phyllodes tumours should be widely excised (mastectomy if the lesion is large)
features breast cyst
Usually presents as a smooth discrete lump (may be fluctuant). Small increased risk of breast cancer (especially if younger)
mx breast cyst
Cysts should be aspirated, those which are blood stained or persistently refill should be biopsied or excised
presentation fat necrosis
More common in obese women with large breasts
May follow trivial or unnoticed trauma
Initial inflammatory response, the lesion is typical firm and round but may develop into a hard, irregular breast lump
mx fat necrosis
Rare and may mimic breast cancer so further investigation is always warranted
Imaging and core biopsy
features duct papilloma
Usually present with nipple discharge. No increase risk of malignancy
mx duct papilloma
Microdochectomy
features lactational breast abscess
Infectious mastitis->accumulation of pus -> lactational breast abscess. Staphylococcus aureus
mx lactational breast abscess
Incision and drainage or needle aspiration, antibiotics according to local protocol
features puerperal mastitis
unilateral and typically presents 1 week postpartum. painful, tender, red and hot breast
mx puerperal mastitis
Continue breastfeeding. If sx don’t improve: flucloxacillin for 10-14 days
features fibroadenosis
Most common in middle-aged women
‘Lumpy’ breasts which may be painful. Symptoms may worsen prior to menstruation
mx fibroadenosis
supportive
features mammary duct ectasia
Dilatation of the large breast ducts
Most common around the menopause
May present with a tender lump around the areola +/- a green nipple discharge
If ruptures may cause local inflammation, sometimes referred to as ‘plasma cell mastitis
mx mammary duct ectasia
Patients with troublesome nipple discharge may be treated by microdochectomy (if young) or total duct excision (if older)
features cyclical mastalgia
Younger, varies in intensity according to the phase of the menstrual cycle
my cyclical mastalgia
supportive
predisposing factors for breast cancer
BRCA1, BRCA2 genes - 40% lifetime risk of breast/ovarian cancer,
1st degree relative premenopausal relative with breast cancer (e.g. mother)
nulliparity/1st pregnancy > 30 yrs (twice risk of women having 1st child < 25 yrs)
early menarche, late menopause
combined HRT (relative risk increase * 1.023/year of use)
combined oral contraceptive use
past breast cancer
not breastfeeding
ionising radiation
p53 gene mutations
obesity
previous surgery for benign disease (?more follow-up, scar hides lump)
presentation pagets disease of breast
intraductal carcinoma associated with a reddening and thickening (may resemble eczematous changes) of the nipple/areola
breast cancer staging
T1-4
N0-3
M0-1
types of breast cancer
Invasive ductal carcinomas are the most common type. Some may arise as a result of ductal carcinoma in situ (DCIS)
Other common types: invasive lobular carcinoma, ductal carcinoma in situ, lobular carcinoma in situ
medulary breast carcinoma
younger patients and those with BRCA1 mutations, often significant lymphocytic infiltration surrounding the tumour
malignant phyllodes tumour
fibroepithelial origin, commonly presents in women in their 40s or 50s. present similarly to fibroadenoma. On mammography-a round breast lesion with well-defined edges
inflammatory breast cancer
where cancerous cells block the lymph drainage resulting in an inflamed appearance of the breast. This accounts for around 1 in 10,000 cases of breast cancer
mx breast cancer
Surgery: offered to most patients. Mastectomy (multifocal tumour, central tumour, large lesion in small breast, DCIS>4) OR wide local excision (peripheral lesion, solitary lesion, small lesion in a big breast, DCIS<4cm) +/- axillary node clearance. Followed by reconstruction.
Radiotherapy: offered depending on tumour and surgery type
hormone therapy:
biological therapy:
Chemotherapy: may be used before or after surgery
tx for HER 2 +ve tumours
trastuzumab
tx for ER +ve tumours
tamoxifen in pre/peri-menopausal or anastrozole in post menopausal
cystocele
Prolapse of anterior vaginal wall involving the bladder
uterine prolapse
Prolapse of uterus, cervix and upper vagina
enterocele
Prolapse of upper posterior wall of vagina
rectocele
Prolapse of lower posterior wall of vagina, usually involving the anterior wall of rectum
stress incontinence
involuntary leakage of urine during increased intra-abdominal pressure
urge incontinence
overactive bladder syndrome - is the presence of urgency, usually with frequency and nocturia, in the absence of urinary tract infection or any other obvious pathology.
overflow incontinence
due tobladder outlet obstruction, e.g. due to prostate enlargement
functional incontinence
Causes include dementia, sedating medication and injury/illness resulting in decreased ambulation
RF for urinary incontinence
advancing age
previous pregnancy and childbirth
high body mass index
hysterectomy
family history
investigations for urinary incontinence
exclude infection of the urinary tract.
Frequency/volume charts: Stress – normal frequency and bladder capacity, Urge – increased frequency
Urodynamic studies – performed in stress urinary incontinence when considering surgery to confirm the diagnosis and rule out concomitant detrusor over-activity.
mx urge incontinence
bladder retraining(lasts for a minimum of 6 weeks, the idea is to gradually increase the intervals between voiding)
bladder stabilising drugs: antimuscarinics are first-line: oxybutynin (immediate release), tolterodine (immediate release) or darifenacin (once daily preparation). Immediate release oxybutynin should, however, beavoided in ‘frail older women’
mirabegron (abeta-3 agonist) may be useful if there is concern about anticholinergic side-effects infrail elderly patients
mx stress incontinence
pelvic floor muscle training: NICE recommend at least 8 contractions performed 3 times per day for a minimum of 3 months
surgical procedures: e.g. retropubic mid-urethral tape procedures
duloxetinemay be offered to women if they decline surgical procedures: mechanism of action: increased synaptic concentration of noradrenaline and serotonin within the pudendal nerve → increased stimulation of urethral striated muscles within the sphincter → enhanced contraction
prolapse presentation
sensation of pressure, heaviness, ‘bearing-down’
urinary symptoms: incontinence, frequency, urgency
Rectocele often causes constipation rather than urinary sx
mx prolapse
if asymptomatic and mild prolapse then no treatment needed
conservative: weight loss, pelvic floor muscle exercises
ring pessary
Surgery: cystocele/cystourethrocele= anterior colporrhaphy, colposuspension, uterine prolapse = hysterectomy, sacrohysteropexy, rectocele = posterior colporrhaphy
didelphys
Total failure of fusion -> two uterine cavities and cervices
unicornate uterus
One duct failure
‘RUDIMENTARY HORN
One duct develops better than the other
phases of ovarian cycle
follicular
ovulation
luteal
follicular phase ovarian cycle
The follicular phase marks the beginning of a new cycle as follicles (oocytes surrounded by stromal cells) begin to mature and prepare to release an oocyte.
At the start of a new cycle (menses) there is little ovarian hormone production and the follicle begins to develop independently of gonadotropins or ovarian steroids. Due to the low steroid and inhibin levels, there is little negative feedback at the HPG axis, resulting in an increase in FSH and LH levels. These stimulate follicle growth and oestrogen production.
Only one dominant follicle can continue to maturity and complete each menstrual cycle. As oestrogen levels rise, negative feedback reduces FSH levels, and only one follicle can survive, with the other follicles forming polar bodies.
Follicular oestrogen eventually becomes high enough to initiate positive feedback at the HPG axis, increasing levels of GnRH and gonadotropins. However, the effect is only reflected in LH levels (the LH surge) due to the increased follicular inhibin, selectively inhibiting FSH production at the anterior pituitary. Granulosa cells become luteinised and express receptors for LH.
ovulation phase ovarian cycle
In response to the LH surge, the follicle ruptures and the mature oocyte is assisted to the fallopian tube by fimbria. Here it remains viable for fertilisation for around 24 hours.
Following ovulation, the follicle remains luteinised, secreting oestrogen and now also progesterone, reverting back to negative feedback on the HPG axis. This, together with inhibin (inhibits FSH) stalls the cycle in anticipation of fertilisation.
luteal phase ovarian cycle
The corpus luteum is the tissue in the ovary that forms at the site of a ruptured follicle following ovulation. It produces oestrogens, progesterone and inhibin to maintain conditions for fertilisation and implantation.
At the end of the cycle, in the absence of fertilisation, the corpus luteum spontaneously regresses after 14 days. There is a significant fall in hormones, relieving negative feedback, resetting the HPG axis ready to begin the cycle again.
If fertilisation occurs, the syncytiotrophoblast of the embryo produces human chorionic gonadotropin (HcG), exerting a luteinising effect, maintaining the corpus luteum. It is supported by placental HcG and it produces hormones to support the pregnancy. At around 4 months of gestation, the placenta is capable of production of sufficient steroid hormone to control the HPG axis.
phases of the uterine cycle
proliferative
secretory
menses
proliferative phase uterine cycle
Following menses, the proliferative phase runs alongside the follicular phase, preparing the reproductive tract for fertilisation and implantation. Oestrogen initiates fallopian tube formation, thickening of the endometrium, increased growth and motility of the myometrium and production of a thin alkaline cervical mucus (to facilitate sperm transport).
secretory phase uterine cycle
The secretory phase runs alongside the luteal phase. Progesterone stimulates further thickening of the endometrium into a glandular secretory form, thickening of the myometrium, reduction of motility of the myometrium, thick acidic cervical mucus production (a hostile environment to prevent polyspermy), changes in mammary tissue and other metabolic changes.
menses phase uterine cycle
Menses marks the beginning of a new menstrual cycle. It occurs in the absence of fertilisation once the corpus luteum has broken down and the internal lining of the uterus is shed. Menstrual bleeding usually lasts between 2-7 days with 10-80ml blood loss.
what does fsh do
binds to granulosa cells to stimulate follicle growth, permit the conversion of androgens (from theca cells) to oestrogens and stimulate inhibin secretion
what does lh do
theca cells to stimulate production and secretion of androgens
describe the main feedback systems in the menstrual cycle
Moderate oestrogen levels exert negative feedback on the HPG axis
High oestrogen levels (in the absence of progesterone) positively feedback on the HPG axis
Oestrogen in the presence of progesterone exerts negative feedback on the HPG axis
Inhibin selectively inhibits FSH at the anterior pituitary
what is menopause
Amenorrhoea (no menstruation) for 12 months
common perimenopausal sx
hot flushes, urinary incontinence and increased UTIs as well as irregular vaginal bleeding
premature ovarian insufficiency
women under the age of 40 and is characterised by low oestrogen, high gonadotropins and amenorrhoea.
levels of oestrogen post menopause
lower
changes after menopause
Vasomotor Changes: hot flushes. These occur with a red flush starting on the face and spreading down the neck and chest. These are associated with peripheral vasodilation and a transient rise in body temperature. is thought to be due to pulsatile LH release influencing central temperature control.
Urogenital Changes: The uterus and vagina are both tissues which are maintained by circulating oestrogen. After the menopause there is marked atrophy of the vagina and thinning of the myometrium. There is also thinning of vaginal walls and dryness, this can result in dyspareunia (pain during sex). The bladder and urethra share embryological derivation with the uterus and vagina and so these tissues also atrophy with the decrease in circulating oestrogen. This leads to symptoms of urinary incontinence and an increase in urinary tract infections.
Bone Density: Oestrogen protects bone mass and density through reducing the activity of oesteoclasts. With the drop in oestrogen this balance is tipped and there is an increase in bone reabsorption. This results in an acceleration of age related loss of bone density and an increased frequency in fractures, especially of the wrist and hip.
Ischaemic Heart Disease: Oestrogen offers a protective effect against heart disease. It is thought that oestrogen reduces levels of LDL cholesterol whilst raising HDL cholesterol. After the menopause women experience the same frequency of cardiovascular disease as men.
mx menopause
Lifestyle modifications: exercise, wt loss, sleep hygiene
Hormone replacement therapy (HRT)
Non-hormone replacement therapy: Vasomotor symptoms = fluoxetine, citalopram or venlafaxine, Vaginal dryness = vaginal lubricant or moisturiser, Psychological symptoms = self-help groups, cognitive behaviour therapy or antidepressants, Urogenital symptoms = if suffering from urogenital atrophy vaginal oestrogen
what is in HRT
Oestrogens (used to overcome oestrogen deficiency) – oral, transdermal, topical
Progestogen (endometrial protection from oestogen) – oral, transdermal, IUS (mirena
who can have oestrogen only HRT
women without a uterus
what are the types of combines HRT
Cyclically: perimenopausal women who are still having menstrual periods
Continuous: postmenopausal women who are not having menstrual periods
CI HRT
Breast cancer (current / past)
Undiagnosed vaginal bleeding
VTE
Active liver disease
Pregnancy
Thrombophilic disorder
Active / recent angina or MI
Smoking / smoking within 1 yr >35yrs
risks HRT
Breast cancer
Endometrial cancer (if oestrogen alone)
VTECardiovascular disease >60yrs
benefits HRT
Relief of vasomotor symptoms
Relief of urogenital symptoms
Reduced risk of osteoporosis
normal age of puberty
8-14 in females, and between the ages of 10-16 in males.
puberty in females
Thelarche: the beginning of breast development (thelarche). This typically occurs at around age 9-10
Pubarche: the second sign of puberty in girls is typically the growth of hair in the pubic area
Menarche is the first menstrual period and marks the beginning of the menstrual cycles. It normally occurs around 1.5-3 years after thelarche and is due to the increase in FSH and LH
puberty in males
Genital changes: The first sign of puberty in boys is the increase in testicular size
Pubarche: Another pubertal sign in boys is the growth of pubic hair at the base of the penis
tanner stages for male genitalia
Stage 1: Prepubertal
Stage 2: Enlargement of scrotum and testes; scrotum skin reddens
and changes in texture
Stage 3: Enlargement of penis (length at first); further growth of
testes
Stage 4: Increased size of penis with growth in breadth and
development of glans; testes and scrotum larger, scrotum
skin darker
Stage 5: Adult genitalia
tanner stages for breast development
Stage 1: Prepubertal
Stage 2: Breast bud stage with elevation of breast and papilla; enlargement of areola
Stage 3: Further enlargement of breast and areola; no separation of their contour
Stage 4: Areola and papilla form a secondary mound above level of breast
Stage 5: Mature stag
tanner stages for pubic hair
boys and girls
Stage 1: Prepubertal (can see velus hair similar to abdominal wall)
Stage 2: Sparse growth of long, slightly pigmented hair, straight or
curled, at base of penis or along labia
Stage 3: Darker, coarser and more curled hair and begins to extend
laterally
Stage 4: Hair adult in type, but covering smaller area than in adult; no
spread to medial surface of thighs
Stage 5: Adult in type an
tanner stages for growth
Stage 1: M 5-6cm per year, F 5-6cm per year
Stage 2: 5-6cm per year, 7-8cm per year
Stage 3: 7-8cm per year, 8cm per year
Stage 4: 10cm per year, 7cm per year
Stage 5: No further height
increase after 17 years, No further height
increase after 16 years